PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB – Free Report) in a research report report published on Thursday,Benzinga reports. They currently have a $21.00 price target on the stock. Separately, B. Riley reduced their price objective on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating […]
More Stories
Google’s Parent Company to Buy Cybersecurity Startup Wiz for $32 Billion
By Chase Smith Google and its parent company Alphabet Inc. announced a definitive agreement to acquire Wiz Inc., a leading...
FDA Issues Warning on Laughing Gas After Increase in Adverse Events
By Jack Phillips The U.S. Food and Drug Administration (FDA) warned on March 14 that consumers should not use products...
DOGE Says ‘Major Cleanup’ of Social Security Records Underway
By Jack Phillips The Elon Musk-led Department of Government Efficiency (DOGE) has said the Social Security Administration has undertaken a...
White House Hails Recent Drops in Egg and Gas Prices
By Jack Phillips The White House on March 17 announced a drop in egg and gasoline prices, calling it a...
DOGE Says It Entered Peace Institute Building With Police Escort Amid Alleged Standoff
By Jack Phillips The Department of Government Efficiency (DOGE) said its staffers, along with acting U.S. Institute of Peace President...
Barings LLC Sells 238 Shares of JPMorgan Chase & Co. (NYSE:JPM)
Barings LLC lessened its holdings in shares of JPMorgan Chase & Co. (NYSE:JPM) by 11.5% during the 4th quarter, according...